<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-998
Date of Submission: 2024-08-22

This report was submitted by a Other Healthcare Professional from Smith-Johnson Medical Center concerning patient ANON-PX-2076. The subject is an adult female with a significant medical history including type 2 diabetes, seasonal allergies, osteoarthritis, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Intravenous route at a dosage of 142mg, initiated on 2024-06-15 for Hypothyroidism and discontinued on 2024-08-18; Omeprazole (Proton-pump inhibitor) administered via the Subcutaneous route at a dosage of 260mg, initiated on 2024-06-15 for Gastroesophageal reflux disease and discontinued on 2024-08-18.

On approximately 2024-07-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Dizziness. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Tax past large force such. Soon cost child show. Impact director really small morning sense.</data>
report_id: ADR-2024-998
report_date: '2024-08-22'
patient_details:
  patient_id: ANON-PX-2076
  gender: Female
  relevant_history:
  - type 2 diabetes
  - seasonal allergies
  - osteoarthritis
  - migraines
suspected_drugs:
- drug_name: Levothyroxine
  dosage: 142mg
  route_of_administration: Intravenous
  start_date: '2024-06-15'
  indication_for_use: Hypothyroidism
  drug_class: Thyroid hormone
  end_date: '2024-08-18'
- drug_name: Omeprazole
  dosage: 260mg
  route_of_administration: Subcutaneous
  start_date: '2024-06-15'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
  end_date: '2024-08-18'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2024-07-11'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Dizziness
  onset_date: '2024-07-11'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 5
reporting_facility: Smith-Johnson Medical Center
reporter_type: Other Healthcare Professional
notes: Tax past large force such. Soon cost child show. Impact director really small
  morning sense.
